ER+/HER2+ breast cancer: are we really de-escalating?

Ann Oncol 2019 Apr 16. Epub 2019 Apr 16.

Medicine, Institut Jules Bordet and L'Université Libre de Bruxelles, Brussels, Belgium.

Download full-text PDF

Source
http://dx.doi.org/10.1093/annonc/mdz130DOI Listing

Still can't find the full text of the article?

We can help you send a request to the authors directly.
April 2019
1 Read

Publication Analysis

Top Keywords

breast cancer
4
cancer de-escalating?
4
er+/her2+ breast
4
de-escalating?
1
cancer
1
er+/her2+
1

References

(Supplied by CrossRef)
Six versus 12 months of adjuvant trastuzumab in combination with dose-dense chemotherapy for women with HER2-positive breast cancer: a multicenter randomized study by the Hellenic Oncology Research Group (HORG)
Mavroudis et al.
Ann Oncol 2015

Similar Publications